![Myopathy / Myotubularin 1 / Weakness / Gene delivery / Emerging technologies / Medical genetics / Medical research / Centronuclear myopathy / Biology / Health / Medicine Myopathy / Myotubularin 1 / Weakness / Gene delivery / Emerging technologies / Medical genetics / Medical research / Centronuclear myopathy / Biology / Health / Medicine](https://www.pdfsearch.io/img/f3fedc94966d01c12c3f0c4c1873a388.jpg)
| Document Date: 2015-05-12 13:57:54 Open Document File Size: 101,64 KBShare Result on Facebook
City Gainesville / New Orleans / SAN FRANCISCO / Evry / / Company Genethon / Audentes / Therapeutics Inc. / / Country France / / / Event Business Partnership / / Facility University of Florida / College of Medicine / University of Washington School / / IndustryTerm gene therapy technology / biotechnology / gene therapy products / treatment of Pompe Disease / manufacturing / energy / / MedicalCondition AAV Therapy Attenuates Respiratory Dysfunction / progressive muscle weakness / Hemophilia B / Pompe Disease Pompe Disease / Myotubular Myopathy / severe muscle weakness / disorder / serious / rare diseases / orphan genetic diseases / eye diseases / Pompe Disease / / MedicalTreatment gene therapy / enzyme replacement therapy / / Organization University of Washington / University of Florida / / Person Gray / Mack / Patterson / Todd / / Position Investigator / Vice President of Research and Development / President and Chief Executive Officer / Suite Executive / / Product AT002 / AT001 / / ProvinceOrState Louisiana / Florida / / Technology Gene Therapy / alpha / Cell Therapy / biotechnology / AAV gene therapy technology / Gene Delivery / / URL www.audentestx.com / www.genethon.fr / http /
SocialTag |